Clinical Trials
Rare Disease Patient Platform Raremark Partners With TriNetX
TriNetX, the global health research network that revolutionizes clinical research and enables discoveries through the generation of real-world evidence (RWE), announced that Raremark, a patient-data platform focused on rare disease, has partnered with the TriNetX network to bring more...
Clinical Trials
IQVIA Launches Avacare Clinical Research Network to Increase Patients Clinical and Research Options
IQVIA™ (NYSE: IQV), a leader in human data science, announced the launch of Avacare Clinical Research Network™, a technology-based global site network that opens opportunities for more clinical trials at experienced clinical and research sites. Avacare’s unique analytical tools...
Clinical Trials
CytoDyn Receives IRB Approval to Initiate Phase 2 Basket Trial for 22 Solid Tumor Cancers
CytoDyn Inc , a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, reported that it has received Institutional Review Board (IRB) approval to begin its Phase 2 clinical trial for...
Clinical Trials
Biocons Insulin Manufacturing Facility in Malaysia Completes U.S. FDA Inspection
This is to inform you that the U.S. FDA conducted a pre-approval inspection (PAI) of our subsidiary, Biocon Sdn. Bhd’s Insulins manufacturing facility based in Malaysia, for Insulin Glargine, between Feb 10 and Feb 21, 2020.
At the conclusion of...
Clinical Trials
Spring Bank Pharmaceuticals in Clinical Collaboration With Roche
Spring Bank Pharmaceuticals Inc. said it has entered into a new clinical collaboration with Roche to explore the co-administration of SB 11285, Spring Bank's intravenously-administered stimulator of interferon gene agonist with Roche's PD-L1 checkpoint inhibitor atezolizumab in patients with...
Clinical Trials
Light Chain Bioscience Successfully Completes Factor VIII Mimetic Bispecific Antibody Discovery
Light Chain Bioscience has achieved a milestone and received a payment under its research and collaboration agreement with Takeda Pharmaceutical. The milestone was achieved upon the successful completion of the discovery phase and designation by Takeda of undisclosed bispecific...
Clinical Trials
Chiesi Group Announces Establishment of New Global Rare Diseases Division
Chiesi Farmaceutici S.p.A., an international research-focused healthcare Group (Chiesi Group), announced the formation of Chiesi Global Rare Diseases, a new business unit that will harness the full resources of the Chiesi Group to advance research and new product development...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read















